For patients who received neoadjuvant chemotherapy and found to have an EGFR sensitizing mutation at time of R0 surgical resection, would you offer still offer adjuvant osimertinib?  

This question has several nuances to address with the rapidly evolving therapeutic landscape for early-stage lung cancer, specifically patients with EGFR mutation. First is the question of neoadjuvant therapy and whether genomic testing should be done prior to offering neoadjuvant treatment. With th...